Sherlock Biosciences Named to Fast Company’s First-Ever List of the Next Big Things in Tech

Disruptive Diagnostic Pioneer Honored for Applying the Power of CRISPR Technology to COVID-19 Testing

Cambridge, Mass. – Sherlock Biosciences, an Engineering Biology company dedicated to making diagnostic testing better, faster and more affordable, today announced that it has been named to Fast Company’s inaugural Next Big Things in Tech list for its application of CRISPR technology to its FDA-authorized COVID-19 testing kit. The list honors technology breakthroughs that promise to shape the future of their industries—from healthcare to agriculture to artificial intelligence and more.

The final list, which includes global giants, intrepid startups, and research that’s fresh from the labs, recognizes 65 technologies that are making waves. While not all of the products, services, and technological developments are on the market yet, they’re reaching key milestones in having a positive impact for consumers, businesses, and society at large in the next five years. Fast Company also recognized 33 honorable mentions.

Sherlock Biosciences first broke ground by receiving the first ever FDA authorization of CRISPR technology for its Sherlock™ CRISPR SARS-CoV-2 kit for the rapid detection of the virus that causes COVID-19. Beyond COVID-19, there are additional gaps in at-home testing, and Sherlock is committed to bringing testing into consumers’ homes to make healthcare more accessible.

“The recent COVID-19 global health crisis underscored the dire need for rapid, reliable, and accessible diagnostic testing. Our first-of-its-kind CRISPR-based COVID-19 testing kit has provided a springboard from which we will continue to apply cutting-edge science to create new diagnostics solutions that change the lives of individuals and have a profound impact on society at large,” said Bryan Dechairo, President and CEO of Sherlock Biosciences. “We are honored that our technology was recognized by Fast Company as one of the Next Big Things in Tech 2021. We are determined to put vital health information in the hands of patients so they are empowered to make informed healthcare decisions.”

Fast Company is thrilled to highlight cutting-edge technologies that are solving real-world problems in unexpected ways. From climate change and public health crises to machine learning and security, these technologies will certainly have a profound impact on the future, and we’re honored to bring attention to them today,” says Stephanie Mehta, editor-in-chief of Fast Company.

Click here to see the final list.

The Winter 2021/2022 issue of Fast Company is available online now and will hit newsstands on December 7.

About Fast Company

Fast Company is the only media brand fully dedicated to the vital intersection of business, innovation, and design, engaging the most influential leaders, companies, and thinkers on the future of business. The editor-in-chief is Stephanie Mehta. Headquartered in New York City, Fast Company is published by Mansueto Ventures LLC, along with our sister publication, Inc., and can be found online at fastcompany.com.

About Sherlock Biosciences

Sherlock Biosciences is setting a new standard for molecular diagnostics, bringing answers to the point of need by enabling simple and convenient access to health information. Through its Engineering Biology platforms, CRISPR-based SHERLOCK™ and INSPECTR™, a synthetic-biology-based molecular diagnostics platform that is instrument-free, Sherlock is bringing together the accuracy of PCR testing with the convenience and simplicity of antigen tests for molecular diagnostics at your fingertips. SHERLOCK and INSPECTR can be used in virtually any setting without complex instrumentation, opening up a wide range of potential applications in areas including the home, precision oncology, infection identification, food safety and disease detection. In 2020 the company made history with the first FDA-authorized use of CRISPR technology. For more information please visit www.sherlock.bio.

Contact

Dean Mastrojohn, Goodfuse Communications
dean.mastrojohn@goodfuse.com